Allogenetics provides a unique solution to the problem of organ rejection following transplantation.
Allogenetics has raised $4.4M in total funding. The most recent round was Seed. The last funding was announced in September 2026.
Allogenetics's investors include Carma Fund, NBank Capital, Life Science Valley Wachstumsfond.
Allogenetics is headquartered in Hanover, Germany.
Allogenetics provides a unique solution to the problem of organ rejection following transplantation.
Allogenetics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Allogenetics — Funding & Investors." VCBacked, September 9, 2026, https://www.vcbacked.co/company/allogenetics. Accessed October 28, 2026.
VCBacked. (2026). Allogenetics — Funding & Investors. Retrieved October 28, 2026, from https://www.vcbacked.co/company/allogenetics
{{cite web |title=Allogenetics — Funding & Investors |url=https://www.vcbacked.co/company/allogenetics |website=VCBacked |access-date=October 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated